Skip to Content
MilliporeSigma
All Photos(2)

Key Documents

View All Documentation

T7455

Sigma-Aldrich

Tolvaptan

≥98% (HPLC), powder

Synonym(s):

N-[4-[(7-Chloro-2,3,4,5-tetrahydro-5-hydroxy-1H-1-benzazepin-1-yl)carbonyl]-3-methylphenyl]-2-methylbenzamide, OPC 41061

Sign Into View Organizational & Contract Pricing
All Photos(2)

About This Item

Empirical Formula (Hill Notation):
C26H25ClN2O3
CAS Number:
150683-30-0
Molecular Weight:
448.94
MDL number:
MFCD09838782
UNSPSC Code:
51111800
PubChem Substance ID:
329826866
NACRES:
NA.77

assay

≥98% (HPLC)

form

powder

color

white to tan

solubility

DMSO: ≥15 mg/mL

originator

Sanofi Aventis

storage temp.

2-8°C

SMILES string

Cc1ccccc1C(=O)Nc2ccc(c(C)c2)C(=O)N3CCCC(O)c4cc(Cl)ccc34

InChI

1S/C26H25ClN2O3/c1-16-6-3-4-7-20(16)25(31)28-19-10-11-21(17(2)14-19)26(32)29-13-5-8-24(30)22-15-18(27)9-12-23(22)29/h3-4,6-7,9-12,14-15,24,30H,5,8,13H2,1-2H3,(H,28,31)

InChI key

GYHCTFXIZSNGJT-UHFFFAOYSA-N

Gene Information

human ... AVPR2(554)

Application

Tolvaptan has been used as a V2-selective antagonist for studying its effect on hypertension in mice.

Biochem/physiol Actions

Tolvaptan (OPC 41061) is a potent, orally active non-peptide vasopressin V2 selective antagonist. IC50 = 3 nM at the rat V2 receptor; 29 times more selective for the V2 than for V1a. Tolvaptan has also been shown to inhibit the development of polycystic kidney disease in several animal models.

Features and Benefits

This compound was developed by Sanofi Aventis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Preparation Note

Tolvaptan is soluble in DMSO at a concentration that is greater than or equal to 15 mg/ml.

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Vicente E Torres et al.
The New England journal of medicine, 367(25), 2407-2418 (2012-11-06)
The course of autosomal dominant polycystic kidney disease (ADPKD) is often associated with pain, hypertension, and kidney failure. Preclinical studies indicated that vasopressin V(2)-receptor antagonists inhibit cyst growth and slow the decline of kidney function. In this phase 3, multicenter
Hyponatremia and outcomes in patients with heart failure.
Steven R Goldsmith
Heart (British Cardiac Society), 98(24), 1761-1762 (2012-12-04)
[Vasopressin antagonist in hyponatremia. Rapid and simple control of serum sodium concentration].
MMW Fortschritte der Medizin, 154(22), 78-79 (2013-01-10)
Nicole K Littlejohn et al.
American journal of physiology. Regulatory, integrative and comparative physiology, 304(10), R818-R828 (2013-03-29)
An indispensable role for the brain renin-angiotensin system (RAS) has been documented in most experimental animal models of hypertension. To identify the specific efferent pathway activated by the brain RAS that mediates hypertension, we examined the hypothesis that elevated arginine
Urine osmolality-guided tolvaptan therapy in decompensated heart failure.
Kaoru Dohi et al.
Circulation journal : official journal of the Japanese Circulation Society, 77(2), 313-314 (2012-12-28)
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service